Brief: VBL Therapeutics Selected For EUR 17.5 Mln Of Funding From Horizon Europe EIC Accelerator Program
20/12/2021 12:46
Dec 20 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VBL THERAPEUTICS SELECTED FOR EUR 17.5 MILLION OF FUNDING
FROM
HORIZON EUROPE EIC ACCELERATOR PROGRAM
* VASCULAR BIOGENICS - FUNDS TO BE USED FOR CLINICAL
DEVELOPMENT,
CMC, AND PRE-COMMERCIALIZATION ACTIVITIES FOR OFRA-VEC (VB-111)
Source text for Eikon: ID:nGNXbHxvWg
Further company coverage: VBLT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives